Evaluation of the Relationship Between Socio-demographic Characteristics and Social Support with Adherence to Treatment in Patient with Multiple Sclerosis

Year 2022, Volume: 5 Issue: 2, 75 - 82, 20.12.2022

Gizem Yağmur Yalçın , Ayşe Beser , Murat Kürtüncü

https://doi.org/10.33438/ijdshs.1105516

Abstract

Multiple sclerosis (MS) is a severe autoimmune illness that can be treated with a variety of medications. However, over a third of patients do not adhere to their treatment regimens. Drug compliance may be influenced by social support and demographic factors. This is a cross-sectional study that examines the association between Patient with MS socio-demographic characteristics and social support and their treatment adherence. We used the perceived social support scale and the treatment compliance scale to collect data on socio-demographic factors. We looked at the correlations between the scores on the three scales. We included 155 female, 45 male patients in our study. The mean age of the patients was 36.3±11.8 (±standard deviation). The rate of noncompliant patients was 15.5%. and 56.0% showed moderate-level compliance with their treatment. The mean multi-dimensional perceived social support score was 62.3±18.8. The only socio-demographic feature that impacts the social support and special person subscale scores was the marital status. We found that married patiens had significantly more social support and were significantly higher than divorced patient (p<0.05). This study found that PwMS compliance with their medicines is unaffected by socio-demographic characteristics or perceived social support. Larger patient groups with less perceived social support will need to be studied. On the other hand, this suggests that patient compliance is more influenced by personal factors such illness perception and beliefs than by social support.

Keywords

Multiple sclerosis, treatment compliance, perceived social support

References

• Aghaei, N., Karbandi, S., Gorji, M.A.H., Golkhatmi, M.B., & Alizadeh, B. (2016). Social support in relation to fatigue symptoms among patients with multiple sclerosis. Indian journal of palliative care, 22(2), 163.
• Arroyo, E., Grau, C., Ramo-Tello, C., Parra, J., Sanchez-Solino, O., & GAP Study Group. (2011). Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project. European neurology, 65(2), 59-67.
• Bergvall, N., Petrilla, A. A., Karkare, S.U., Lahoz, R., Agashivala, N., Pradhan, A. & Korn, J. R. (2014). Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Journal of medical economics, 17(10), 696-707.
• Cunningham, A., Gottberg, K., Von Koch, L., & Hillert, J. (2010). Non‐adherence to interferon beta therapy in Swedish patients with multiple sclerosis. Acta neurologica scandinavica, 121(3), 154-160.
• Costa, D.C., Sá, M. J., & Calheiros, J.M. (2017). Social support network and quality of life in multiple sclerosis patients. Arquivos de Neuro-Psiquiatria, 75, 267-271.
• Çobanoğlu, Z.S.Ü., Aker, T., & Çobanoğlu, N. (2003). Treatment compliance problems in patients with schizophrenia and other psychotic disorders. Thinking Man, 16(4), 211-8.
• DiMatteo, M. R. (2004). Social support and patient adherence to medical treatment: a meta-analysis. Health psychology, 23(2), 207.
• Eker, D., & Arkar, H. (1995). Perceived social support: psychometric properties of the MSPSS in normal and pathological groups in a developing country. Social psychiatry and psychiatric epidemiology, 30(3), 121-126.
• Evans, C., Tam, J., Kingwell, E., Oger, J., & Tremlett, H. (2012). Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clinical therapeutics, 34(2), 341-350.
• Fernández, O., Agüera, J., Izquierdo, G., Millán-Pascual, J., Ramio i Torrenta, L., Oliva, P., & Group on Adherence to IFNb-1b in Spain. (2012). Adherence to interferon β-1b treatment in patients with multiple sclerosis in Spain. PLoS One, 7(5), e35600.
• Köşkderelioğlu, A., Gedizlioğlu, M., Ortan, P., & Öcek, Ö. (2015). Multiple skleroz hastalarında immunmodulatör tedaviye uyumun değerlendirilmesi. Archives of Neuropsychiatry, 52, 376-379.
• Langford, C. P. H., Bowsher, J., Maloney, J. P., & Lillis, P. P. (1997). Social support: a conceptual analysis. Journal of advanced nursing, 25(1), 95-100.
• Lilympaki, I., Makri, A., Vlantousi, K., Koutelekos, I., Babatsikou, F., & Polikandrioti, M. (2016). Effect of perceived social support on the levels of anxiety and depression of hemodialysis patients. Materia socio-medica, 28(5), 361.
• Meyniel, C., Spelman, T., Jokubaitis, V.G., Trojano, M., Izquierdo, G., Grand’Maison, F. & MSBasis Study Group. (2012). Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PloS one, 7(6), e38661.
• McKay, K. A., Tremlett, H., Fisk, J.D., Zhang, T., Patten, S. B., Kastrukoff, L., & Marrie, R. A. (2018). Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology, 90(15), e1316-e1323.
• Mohr, D.C., Classen, C., & Barrera, M. (2004). The relationship between social support, depression and treatment for depression in people with multiple sclerosis. Psychological medicine, 34(3), 533-541.
• Motl, R.W., McAuley, E., Snook, E.M., & Gliottoni, R. C. (2009). Physical activity and quality of life in multiple sclerosis: intermediary roles of disability, fatigue, mood, pain, self-efficacy and social support. Psychology, health & medicine, 14(1), 111-124.
• Mohr, D.C., Classen, C., & Barrera, M. (2004). The relationship between social support, depression and treatment for depression in people with multiple sclerosis. Psychological medicine, 34(3), 533-541.
• Morisky, D.E., Green, L.W., & Levine, D.M. (1986). Concurrent and predictive validity of a self-reported measure of medication adherence. Medical care, 67-74.
• Mozo-Dutton, L., Simpson, J., & Boot, J. (2012). MS and me: exploring the impact of multiple sclerosis on perceptions of self. Disability and rehabilitation, 34(14), 1208-1217.
• Neter, E., Glass-Marmor, L., Wolkowitz, A., Lavi, I., & Miller, A. (2021). Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis. BMC neurology, 21(1), 1-9.
• O'Rourke, K.E., & Hutchinson, M. (2005). Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Multiple Sclerosis Journal, 11(1), 46-50.
• Ozdemİr, L., & AŞİret, G.D. (2011). A Holistic Look at Patients With Multiple Sclerosis: Focusing on Social Life, Household and Employment Issues. Turkish Journal of Physical Medicine & Rehabilitation/Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi, 57(1).
• Popova, E.V., Novikova, K.V., Khachanova, N. V., Konovalova, O.E., Kozhieva, M.K., Davydovskaya, M.V., & Boyko, A.N. (2017). The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy. Zhurnal nevrologii i psikhiatrii imeni SS Korsakova, 117(10. Vyp. 2), 48-52.
• Portaccio, E., Zipoli, V., Siracusa, G., Sorbi, S., & Amato, M. P. (2008). Long-term adherence to interferon β therapy in relapsing-remitting multiple sclerosis. European neurology, 59(3-4), 131-135.
• Río, J., Porcel, J., Téllez, N., Sánchez-Betancourt, A., Tintoré, M. A., Arévalo, M. J., ... & Montalban, X. (2005). Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis Journal, 11(3), 306-309.
• Sabaté, E., & Sabaté, E. (Eds.). (2003). Adherence to long-term therapies: evidence for action. World Health Organization.
• Schwartz, C., & Frohner, R. (2005). Contribution of demographic, medical, and social support variables in predicting the mental health dimension of quality of life among people with multiple sclerosis. Health & Social Work, 30(3), 203-212.
• Steinberg, S.C., Faris, R. J., Chang, C.F., Chan, A., & Tankersley, M. A. (2010). Impact of adherence to interferons in the treatment of multiple sclerosis. Clinical drug investigation, 30(2), 89-100.
• Tavares, N.U.L., Bertoldi, A.D., Mengue, S.S., Arrais, P.S.D., Luiza, V.L., Oliveira, M.A., ... & Pizzol, T.D.S.D. (2016). Factors associated with low adherence to medicine treatment for chronic diseases in Brazil. Revista de Saúde Pública, 50, 10s.
• Treadaway, K., Cutter, G., Salter, A., Lynch, S., Simsarian, J., Corboy, J., ... & Frohman, E. M. (2009). Factors that influence adherence with disease-modifying therapy in MS. Journal of neurology, 256(4), 568-576.
• Vural, B., Acar, Ö. T., Topsever, P., & Filiz, T. M. (2012). Modifiye Morisky ölçeğinin türkçe geçerlilik güvenilirlik çalışması. The Journal of Turkish Family Physician, 3(4), 17-20.
• Zimet, G. D., Dahlem, N. W., Zimet, S. G., & Farley, G. K. (1988). The multidimensional scale of perceived social support. Journal of personality assessment, 52(1), 30-41